Entering text into the input field will update the search result below

Neurocrine Biosciences: A Quality Biopharma To Consider On Any Pullbacks

May 06, 2020 12:01 PM ETNeurocrine Biosciences, Inc. (NBIX)3 Comments
Andy Jones profile picture
Andy Jones


  • Neurocrine Biosciences has a soon to be blockbuster in Ingrezza that is bringing in solid free cash flow.
  • Neurocrine has used that cash flow to fill its pipeline with several early, mid, and late stage therapies.
  • Neurocrine shares look fairly valued based on both current and forward discounted P/S and P/E ratios.

Neurocrine Biosciences (NASDAQ:NBIX) is a biopharma company focused on treating CNS and endocrine disorders. Neurocrine has been cash flow positive for the last 2 years off the back of strong sales of Ingrezza, a soon-to-be blockbuster used to treat tardive dyskinesia. Rather than resting on its laurels, Neurocrine is reinvesting that cash flow to develop a broad pipeline of potential therapies that could meaningfully add to its upside over the next few years. Much like I described with Horizon Therapeutics, Neurocrine has a strong business model that gives me confidence that it can sustain more growth and innovation moving forward—things I definitely look for when considering a new investment. Sales and earnings-based metrics though make me think Neurocrine is probably pretty fairly valued right now.

Ingrezza Provides Neurocrine With A Strong Foundation Of Revenue

Ingrezza has almost single-handedly gotten the company to positive cash flow, and now Neurocrine is reinvesting into future growth via the pipeline. Ingrezza is a VMAT2 inhibitor used to treat tardive dyskinesia. Dopamine has been shown to be involved in the disease pathology of tardive dyskinesia, and Ingrezza is thought to have its effect by blocking dopamine release. Ingrezza brought in $752.9 million of Neurocrine’s $788.1 million in total revenue in 2019, up from $409.6 million in 2018.

Figure 1: Ingrezza Sales Chart (source: corporate presentation)

Ingrezza growth is expected to continue at a good pace. Although Ingrezza is being researched for an additional indication for chorea in Huntington’s disease, peak sales estimates that I’ve seen for tardive dyskinesia alone range from $1 billion to $2 billion. Q4 2019 sales of Ingrezza would annualize to about $950 million, which would still be 21% growth over 2019 even if quarterly prescriptions bucked the clear growth trend you can see if Figure 1.

Neurocrine also receives royalty payments

This article was written by

Andy Jones profile picture
I have a value investing background and look for biotech stocks with a wide margin of safety. I tend to focus on companies that are somewhat off the beaten path. Anything I write is simply my personal opinion and should not be taken as trading advice.

Analyst’s Disclosure: I am/we are long NBIX. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I’m not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor the timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself without notification. The thesis that I presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as a recommendation to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. You are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance as financial circumstances are individualized.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.